A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD)

  • Jicha, Gregory (PI)
  • Bardach, Shoshana (Former CoI)
  • Caban-Holt, Allison (Former CoI)

Grants and Contracts Details

StatusFinished
Effective start/end date3/1/18 → 3/4/22

Funding

  • Novartis (domestic): $385,744.00